

CLAIMS

1. An anti-CD38 antibody for use in treating an individual in need thereof, wherein at least a first intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).
2. Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least a first intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).
3. The anti-CD38 antibody for use according to claim 1 or the use of claim 2 wherein the anti-CD38 antibody is isatuximab.
4. The anti-CD38 antibody for use according to claim 1 or 3 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.
5. The anti-CD38 antibody for use of any one of claims 1 and 3-4 or the use of any one of claims 2-3, wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is

increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused.

6. The anti-CD38 antibody for use of any one of claims 1 and 3-4 or the use of any one of claims 2-3, wherein the first infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 12.5 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

7. The anti-CD38 antibody for use according to any one of claims 1 and 3-6, or the use of any one of claims 2-3 and 5-6, at least a second intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml.

8. The anti-CD38 antibody for use or the use of claim 7, wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused.

9. The anti-CD38 antibody for use or the use of claim 7, wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, 100 mL/hour for a second 30 minutes, 200 mL for the third 30 minutes, and 300 mL/hour after the third 30 minutes until the 250 ml volume is infused.

10. The anti-CD38 antibody for use or the use of claim 7, wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 25 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

11. The anti-CD38 antibody for use or the use of any one of claims 7-10, wherein at least a third intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml.

12. The anti-CD38 antibody for use or the use of claim 11, wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume is infused.

13. The anti-CD38 antibody for use or the use of claim 11, wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.
14. The anti-CD38 antibody for use or the use of any one of claims 11-13, comprising a fourth intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml.
15. The anti-CD38 antibody for use or the use of claim 14, wherein the fourth intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.
16. The anti-CD38 antibody for use or the use of claim 14, wherein the fourth intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.
17. The anti-CD38 antibody for use or the use of any one of claims 14-16, wherein the anti-CD38 antibody is to be administered in a first 28-day cycle, wherein the first intravenous infusion of the anti-CD38 antibody is to be administered on Day 1, the second intravenous infusion of the anti-CD38 antibody is to be administered on Day 8, the third intravenous infusion of the anti-CD38 antibody is to be administered on Day 15, and the fourth intravenous infusion of the anti-CD38 antibody is to be administered on Day 22 the first 28-day cycle.
18. The anti-CD38 antibody for use or the use of any one of claims 14-17, wherein one or more subsequent intravenous infusions of the anti-CD38 antibody are to be administered to the individual following the fourth intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml for each of the one or more subsequent intravenous infusions.
19. The anti-CD38 antibody for use or the use of claim 18, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

20. The anti-CD38 antibody for use or the use of claim 18, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

21. The anti-CD38 antibody for use or the use of any one of claims 18-20, wherein the anti-CD38 antibody is to be administered in one or more subsequent 28-day cycles following the first 28-day cycle, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the fourth intravenous infusion is to be administered on Days 1 and 15 of each of the one or more subsequent 28-day cycles following the first 28-day cycle.

22. An anti-CD38 antibody for use in treating an individual in need thereof, wherein at least three intravenous infusions of the anti-CD38 antibody are to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6);

wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused;

wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused; and

wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

23. Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least three intravenous infusion of the anti-CD38 antibody is to be administered to the individual, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the dose of the anti-CD38 antibody is in a volume of 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6);

wherein the first intravenous infusion of the anti-CD38 antibody is to be administered to the individual at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml volume is infused;

wherein the second intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 mL/hr a second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused; and

wherein the third intravenous infusion of the anti-CD38 is to be administered to the individual at an infusion rate of 100 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml volume is infused.

24. The anti-CD38 antibody for use according to claim 22 or the use of claim 23 wherein the anti-CD38 antibody is isatuximab.

25. The anti-CD38 antibody for use according to claim 22 or 24 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.

26. The anti-CD38 antibody for use according to any one of claims 21 and 23-25, or the use of any one of claims 22-24, wherein one or more subsequent intravenous infusions of the anti-CD38 antibody are to be administered following the third intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml for each of the one or more subsequent intravenous infusions.

27. The anti-CD38 antibody for use or the use of claim 26, wherein each of the one or more subsequent intravenous infusions of the anti-CD38 antibody following the third intravenous infusion is to be administered to the individual at an infusion rate of 200 ml/hour until the 250 ml volume infused.

28. An anti-CD38 antibody for use in treating an individual in need thereof, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the volume of each dose of the anti-CD38 antibody is 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

29. Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in an individual, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg, wherein the volume of each dose of the anti-CD38 antibody is 250 ml, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

30. The anti-CD38 antibody for use according to claim 28 or the use of claim 29 wherein the anti-CD38 antibody is isatuximab.

31. The anti-CD38 antibody for use according to claim 28 or 30 wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.

32. The anti-CD38 antibody for use according to any one of claims 28 and 30-31, or the use of any one of claims 29-30 wherein the anti-CD38 antibody is to be administered in a first 28-day cycle, and wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of the first 28-day cycle.

33. The anti-CD38 antibody for use or the use of claim 32, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of the first 28 day cycle at an infusion rate of 25 mL/hour for a first hour, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first hour to a maximum infusion rate of 150 mL/hour until the 250 ml dose of the anti-CD38 antibody is infused.

34. The anti-CD38 antibody for use or the use of claim 32, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of the first 28 day cycle at an infusion rate of 12.5 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 25 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

35. The anti-CD38 antibody for use or the use of any one of claims 32-34 wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 50 mL/hour for a first 30 minutes, wherein the infusion rate is increased by 50 ml/hr for an second 30 minutes, and wherein the infusion rate is increased by 100 mL/hour every 30 minutes after the second 30 minutes to a maximum infusion rate of 200 mL/hour until the 250 ml volume is infused.

36. The anti-CD38 antibody for use or the use of any one of claims 32-34, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 50 mL/hour for a first 30 minutes, 100 mL/hour for a second 30 minutes, 200 mL for the third 30 minutes, and 300 mL/hour after the third 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

37. The anti-CD38 antibody for use or the use of any one of claims 32-34, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 8 of the first 28 day cycle at an infusion rate of 25 mL/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

38. The anti-CD38 antibody for use or the use of any one of claims 32-37, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of the first 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

39. The anti-CD38 antibody for use or the use of any one of claims 32-37, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of the first 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

40. The anti-CD38 antibody for use or the use of any one of claims 32-39, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 22 of the first 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

41. The anti-CD38 antibody for use or the use of any one of claims 32-39, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 22 of the first 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

42. The anti-CD38 antibody for use or the use of any one of claims 32-41, wherein the anti-CD38 antibody is to be further administered in one or more subsequent 28-day cycles, and wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg on Days 1 and 15 of each subsequent 28 day cycle, wherein the volume of each dose of the anti-CD38 antibody to be administered in the one or more subsequent cycles is 250 ml.

43. The anti-CD38 antibody for use or the use of claim 42, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of each subsequent 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

44. The anti-CD38 antibody for use or the use of claim 42, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 1 of each subsequent 28-day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

45. The anti-CD38 antibody for use or the use of any one of claims 42-44, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of each subsequent 28-day cycle at an infusion rate of 200 ml/hour until the 250 ml dose of the anti-CD38 antibody is infused.

46. The anti-CD38 antibody for use or the use of any one of claims 42-44, wherein the anti-CD38 antibody is to be administered to the individual via intravenous infusion on Day 15 of each subsequent 28 day cycle at an infusion rate of 100 ml/hour for a first 30 minutes, and wherein the infusion rate is increased by 50 mL/hour every 30 minutes after the first 30 minutes until the 250 ml dose of the anti-CD38 antibody is infused.

47. An anti-CD38 antibody for use in treating an individual in need thereof, wherein at least a first dose of the anti-CD38 antibody is to be safely administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration of about 1.5 and about 6.5 hours, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

48. Use of an anti-CD38 antibody in the manufacture of a medicament for treating multiple myeloma in a human individual, wherein at least a first dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the first dose is infused over a duration of about 1.5 and about 6.5 hours, and wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).

49. The anti-CD38 antibody for use according to claim 47 or the use of claim 48, wherein the anti-CD38 antibody is isatuximab.

50. The anti-CD38 antibody for use according to claim 47 or 49, wherein the anti-CD38 antibody is for the treatment of a disease or disorder, optionally wherein the disease or disorder is multiple myeloma.

51. The anti-CD38 antibody for use according to any one of claims 47 and 49-50, or the use of any one of claims 48-49, wherein at least a second dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the second dose is infused over a duration of about 0.5 and 3.5 hours.

52. The anti-CD38 antibody for use according to any one of claims 41 and 43-45, or the use of any one of claims 42-45, wherein at least a third dose of the anti-CD38 antibody is to be administered to the individual via intravenous infusion, wherein the anti-CD38 antibody is to be administered at a dose of at least 10 mg/kg in a volume of 250 ml, wherein the third dose is infused over a duration of about 0.5 and 1.5 hours.

53. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an infusion reaction (IR).

54. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an IR greater than Grade 1 in severity.

55. The anti-CD38 antibody for use according to any one of 1, 3-22, 24-28, 30-47, and 49-52, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-52, wherein the administration of the anti-CD38 antibody does not result in the individual experiencing an IR of Grade 2 or greater in severity.

56. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-55, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-55,

wherein the at least 10 mg/kg dose of the anti-CD38 antibody in the volume of 250 ml further comprises 0.9% sodium chloride or 5% dextrose.

57. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-56, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-56, wherein the individual does not receive premedication with one or more of an analgesic, an antacid, an anti-inflammatory agent, an antihistamine prior for the purpose of preventing or minimizing an infusion reaction prior to the administration of the anti-CD38 antibody via intravenous infusion.

58. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-57, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-57, wherein the dose of anti-CD38 antibody is 10 mg/kg or 20 mg/kg.

59. An anti-CD38 antibody for use in treating multiple myeloma in an individual, wherein an anti-CD38 antibody comprises (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6), pomalidomide, and dexamethasone,

wherein the anti-CD38 antibody is to be administered in 28-day cycles;

wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of a first 28-day cycle;

wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle;

and wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg or 20 mg/kg.

60. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO:

5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6), pomalidomide, and dexamethasone, in the manufacture of a medicament for treating multiple myeloma in a human individual,

wherein the anti-CD38 antibody is to be administered in 28-day cycles;

wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of a first 28-day cycle;

wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle;

and wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg or 20 mg/kg.

61. The anti-CD38 antibody for use according to claim 59 or the use of claim 60, wherein the individual has at least one high-risk cytogenetic abnormality selected from: 17p deletion, 4(4; 14) translocation, and t(14;16) translocation.

62. The anti-CD38 antibody for use or the use of claim 61, wherein the individual has at least two high-risk cytogenetic abnormalities.

63. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-62 or the use of any one of claims 5-21, 26-27, 32-46, and 51-62, wherein the multiple myeloma is relapsed/refractory multiple myeloma.

64. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-63 or the use of any one of claims 5-21, 26-27, 32-46, and 51-63, wherein the individual was refractory to the most recent prior therapy for multiple myeloma.

65. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-64 or the use of any one of claims 5-21, 26-27, 32-46, and 51-64, wherein the individual is refractory to lenalidomide.

66. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-65 or the use of any one of claims 5-21, 26-27, 32-46, and 51-65, wherein the most recent prior therapy was lenalidomide.

67. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-66 or the use of any one of claims 5-21, 26-27, 32-46, and 51-66, wherein the individual is refractory to a proteasome inhibitor.

68. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-67 or the use of any one of claims 5-21, 26-27, 32-46, and 51-67, wherein the most recent prior therapy was a proteasome inhibitor.

69. The anti-CD38 antibody for use or the use of claim 67 or 68, wherein the proteasome inhibitor is selected from the group consisting of: bortezomib, carfilzomib, marizomib, oprozomib, and ixazomib.

70. The anti-CD38 antibody for use or the use of any one of claims 64-69, wherein the lenalidomide and the proteasome inhibitor were administered in combination.

71. The anti-CD38 antibody for use according to any one of claims 1, 3-22, 24-28, 30-47, and 49-70, or the use of any one of claims 2-3, 5-21, 23-24, 26-27, 29-30, 32-46, 48-49, and 51-70, wherein the individual has a respiratory disorder, thoracic disorder, and/or mediastinal disorder.

72. The anti-CD38 antibody for use or use of claim 71, wherein the respiratory disorder is chronic obstructive pulmonary disorder (COPD).

73. The anti-CD38 antibody for use or use of claim 71, wherein the respiratory disorder is asthma.

74. The anti-CD38 antibody for use or use of claim 71, wherein the respiratory disorder is bronchospasm.

75. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-74 or the use of any one of claims 5-21, 26-27, 32-46, and 51-74, wherein the individual has received at least two prior therapies for multiple myeloma.

76. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-75 or the use of any one of claims 5-21, 26-27, 32-46, and 51-75, wherein the individual has received at least three prior therapies for multiple myeloma.

77. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-76 or the use of any one of claims 5-21, 26-27, 32-46, and 51-76, wherein the anti-CD38 antibody is to be administered in conjunction with at least one additional agent.

78. The anti-CD38 antibody for use or the use of claim 77, wherein the at least one additional agent comprises an immunomodulatory drug.
79. The anti-CD38 antibody for use or the use of claim 78, wherein the immunomodulatory drug is lenalidomide or pomalidomide.
80. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-79 or the use of any one of claims 5-21, 26-27, 32-46, and 51-79, wherein the at least one additional agent comprises a proteasome inhibitor.
81. The anti-CD38 antibody for use or the use of claim 80, wherein the proteasome inhibitor is bortezomib, carfilzomib, marizomib, oprozomib, and ixazomib.
82. The anti-CD38 antibody for use of any one of claims 4-21, 25-27, 31-46, and 50-81 or the use of any one of claims 5-21, 26-27, 32-46, and 51-81, wherein the at least one additional agent comprises a corticosteroid.
83. The anti-CD38 antibody for use or the use of 82, wherein the corticosteroid is dexamethasone.
84. A kit comprising isatuximab for treating an individual having multiple myeloma according to the use of any one of claims 5-21, 26-27, 32-46, and 51-83.
85. An intravenous bag containing between about 360 mg and 1600 mg of an anti-CD38 antibody in a volume of 250 ml, wherein the wherein the anti-CD38 antibody comprises (a) a heavy chain variable domain (VH) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (VL) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6).